AusBiotech appoints global life sciences fund manager as new board member


Tuesday, 26 March, 2013

AusBiotech has announced the appointment of Lawrence Gozlan as a non-executive director, bringing to the board global capital markets experience and specialist knowledge in life sciences investing.

Gozlan is the Chief Investment Officer and founder of Scientia Capital, a specialised global investment fund focused exclusively in life sciences which manages investments for institutional investors, family offices and high net worth individuals. Prior to this, he was responsible for the largest biotechnology investment portfolio in Australia as the institutional biotechnology analyst at QIC (Queensland Investment Corporation), an investment fund with over $60 billion under management.

Gozlan was previously the senior biotechnology analyst at Foster Stockbroking and advised numerous life sciences companies in corporate finance at Deloitte. He is a board member of several public and private healthcare companies and has presented at numerous international life science conferences. He holds a Bachelor of Science with Honours in microbiology and immunology from the University of Melbourne specialising in neurodegenerative diseases.

AusBiotech Chairman Dr Deborah Rathjen welcomed Gozlan’s appointment and said his experience and background will be a great addition to the biotechnology industry’s peak body.

“It is a pleasure to welcome Lawrence to the AusBiotech Board. His deep experience in global biotech investing will be helpful in bringing forward new initiatives targeting investment into Australian companies,” she said.

Gozlan was pleased to accept the appointment and said: “I am delighted to join the board of AusBiotech during this exciting time in the Australian life sciences industry. By assuming this role, I look forward to helping advance policies that will enable people around the world to benefit from the work that Australian companies carry out.”

The new AusBiotech Board of Directors is:

  • Dr Deborah Rathjen (Chair)
  • Dr Anna Lavelle (Chief Executive Officer)
  • Dr Meera Verma
  • Michelle Burke
  • Peter Turvey
  • Dr Greg Roger
  • Lawrence Gozlan
Related News

Cancer drug eliminates bone metastasis in lab models

Researchers have developed a novel treatment that is specific to breast cancer bone metastasis...

TGA rejects Alzheimer's drug due to safety concerns

The TGA determined that the demonstrated efficacy of lecanemab in treating Alzheimer's did...

Defective sperm doubles pre-eclampsia risk in IVF patients

A high proportion of the father's spermatozoa possessing DNA strand breaks is associated with...


  • All content Copyright © 2024 Westwick-Farrow Pty Ltd